- Email: [email protected]
4625015 Broad spectrum influenza antisera
182
PATENT ABSTRACTS prising concentrating the antigen, precipitating the antigen, purifying the antigen by adsorption to an immunoaffinity column, eluting the antigen and fractionating the antigen on an anion exchange bed.
insoluble in basic solution, having a particular spectrophotometric absorption and an amino acid residue composition of high proportions of glutamic and aspartic acids and high ratios of glutamic and aspartic acids to histidine.
4624921 4624932 HUMAN LYMPHOBLASTOLD CELL LINE AND HYBRIDOMAS DERIVED THEREFROM James W Larrick. Andrew R Raubitschek. Kenneth Truitt assigned to Cetus Corporation A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human*human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.
4624925 HYBRID CELL LINE FOR PRODUCING MONOCLONAL ANTIBODY TO A HUMAN EARLY THYMOCYTE ANTIGENS, ANTIBODY, AND METHODS Patrick C Kung, Gideo Goldstein assigned to Ortho Pharmaceutical Corporation Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAFI mice with P3X63Ag8UI myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
RECOGNINS AND THEIR CHEMORECIPROCALS Samue Bogoch A product, Astrocytin, derived from brain cancer cells growing in vivo, and the method of preparing same. Astrocytin may be complexed with an inert carrier, such as bromoacetyl cellulose, and employed in tests for brain tumors. The antibody to Astrocytin is also prepared. A complex of Astrocytin and an inert carrier may be further complexed to anti-Astrocytin.
4625014 CELL-DELIVERY
AGENT
Peter D Senter, John M Lambert, Walter A Blattier assigned to Dana-Farber Cancer Institute Inc A photo-cleavable compound for delivery and release of a biologically active substance to selected target cells; the compound includes a binding partner for a specific cell-surface receptor of those target cells, the biologically active substance to be delivered, and a photo-cleavable bridge between the binding partner and the biologically active substance. When the compound is exposed to a heterogeneous population of target and non-target cells, it binds selectively to the receptors on the surface of the target cells. Exposing the compound to light of selected wave length cleaves it, yielding the active substance.
4624931 RECOGNINS AND THEIR CHEMORECIPROCALS Samue Bogoch The process for producing polypeptide products which are useful in tests for malignant cells is disclosed. The polypeptide products produced by this process are also disclosed. The process employs the steps of extraction of acidic fractionation and formation of a precipitate in the quantitative precipitin test and the Ouchterlony gel diffusion test. The product is characterized by being soluble in acidic solution,
~2~15 BROAD SPECTRUM INFLUENZA ANTISERA Nicola Green, Stephen Alexander assigned to Scripps Clinic & Research Foundation Antisera against synthetic peptides which neutralize influenza viruses of differing hemagglutinin subtypes, provide protection against infection by influenza virus and methods of preparing the same are disclosed.
PATENT ABSTRACTS prising concentrating the antigen, precipitating the antigen, purifying the antigen by adsorption to an immunoaffinity column, eluting the antigen and fractionating the antigen on an anion exchange bed.
insoluble in basic solution, having a particular spectrophotometric absorption and an amino acid residue composition of high proportions of glutamic and aspartic acids and high ratios of glutamic and aspartic acids to histidine.
4624921 4624932 HUMAN LYMPHOBLASTOLD CELL LINE AND HYBRIDOMAS DERIVED THEREFROM James W Larrick. Andrew R Raubitschek. Kenneth Truitt assigned to Cetus Corporation A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human*human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.
4624925 HYBRID CELL LINE FOR PRODUCING MONOCLONAL ANTIBODY TO A HUMAN EARLY THYMOCYTE ANTIGENS, ANTIBODY, AND METHODS Patrick C Kung, Gideo Goldstein assigned to Ortho Pharmaceutical Corporation Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAFI mice with P3X63Ag8UI myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
RECOGNINS AND THEIR CHEMORECIPROCALS Samue Bogoch A product, Astrocytin, derived from brain cancer cells growing in vivo, and the method of preparing same. Astrocytin may be complexed with an inert carrier, such as bromoacetyl cellulose, and employed in tests for brain tumors. The antibody to Astrocytin is also prepared. A complex of Astrocytin and an inert carrier may be further complexed to anti-Astrocytin.
4625014 CELL-DELIVERY
AGENT
Peter D Senter, John M Lambert, Walter A Blattier assigned to Dana-Farber Cancer Institute Inc A photo-cleavable compound for delivery and release of a biologically active substance to selected target cells; the compound includes a binding partner for a specific cell-surface receptor of those target cells, the biologically active substance to be delivered, and a photo-cleavable bridge between the binding partner and the biologically active substance. When the compound is exposed to a heterogeneous population of target and non-target cells, it binds selectively to the receptors on the surface of the target cells. Exposing the compound to light of selected wave length cleaves it, yielding the active substance.
4624931 RECOGNINS AND THEIR CHEMORECIPROCALS Samue Bogoch The process for producing polypeptide products which are useful in tests for malignant cells is disclosed. The polypeptide products produced by this process are also disclosed. The process employs the steps of extraction of acidic fractionation and formation of a precipitate in the quantitative precipitin test and the Ouchterlony gel diffusion test. The product is characterized by being soluble in acidic solution,
~2~15 BROAD SPECTRUM INFLUENZA ANTISERA Nicola Green, Stephen Alexander assigned to Scripps Clinic & Research Foundation Antisera against synthetic peptides which neutralize influenza viruses of differing hemagglutinin subtypes, provide protection against infection by influenza virus and methods of preparing the same are disclosed.